What is Microplate Dx?
Founded in 2017, Microplate Dx is at the forefront of developing advanced solutions for antimicrobial resistance detection. The company's focus on AMR is particularly relevant given the escalating global health crisis posed by drug-resistant infections. This strategic focus positions Microplate Dx as a key player in the burgeoning diagnostics and biotechnology sectors, aiming to provide rapid and accurate detection methods to combat the growing threat of AMR.
How much funding has Microplate Dx raised?
Microplate Dx has raised a total of $4.4M across 3 funding rounds:
Angel/Seed
$611K
Angel/Seed
$3.1M
Private Equity
$645K
Angel/Seed (2022): $611K with participation from Deepbridge Capital and Strathclyde Inspire Entrepreneurs Fund
Angel/Seed (2023): $3.1M led by SIS Ventures, Scottish Enterprise, University of Strathclyde Glasgow, and Deepbridge Capital
Private Equity (2025): $645K, investors not publicly disclosed
Key Investors in Microplate Dx
Deepbridge Capital
Deepbridge Capital is a private investor network that caters to experienced investors and family offices, allowing them to create personalized portfolios of innovative Life Sciences and Technology companies. Members benefit from extensive due diligence, realistic company valuations, and proactive management of investee companies.
SIS Ventures
SIS Ventures is part of the Social Investment Scotland group, focusing on investing in impact-led enterprises that address significant societal challenges. Established in 2018, the company aims to support high-impact organizations through mission-aligned investments.
Scottish Enterprise
Scottish Enterprise is a national economic development agency and a non-departmental public body of the Scottish Government, headquartered in Glasgow, United Kingdom.
What's next for Microplate Dx?
With substantial backing, Microplate Dx is poised for accelerated growth and innovation. The recent major strategic investment signals confidence from investors in the company's technology and market potential. This capital infusion is expected to fuel further research and development, enhance manufacturing capabilities, and expand market reach. The company's trajectory suggests a move towards scaling its operations and solidifying its position as a leader in AMR diagnostics, potentially leading to further funding rounds or strategic partnerships to achieve its long-term objectives.
See full Microplate Dx company page
